Degenerative disc disease — master index¶
Last curated: 2026-08-30 · status: audited
The condition in five sentences. Degenerative disc disease (DDD) describes age-, inheritance- and exposure-associated intervertebral-disc structural change, but the label is not itself a pain diagnosis because degeneration is common in asymptomatic adults (Brinjikji 2015, PMID 25430861). Disc findings are more prevalent in people with low-back pain than controls, yet association does not identify a painful level or establish causality (Brinjikji 2015, PMID 26359154). Genetics, endplate transport, smoking, metabolic factors, matrix loss, inflammation, senescence and altered mechanics interact, replacing a simple “wear and tear” model (Battié 2009, PMID 19111259; Urban 2007, PMID 17260404; Mohd Isa 2022, PMID 36613651). Initial care for nonspecific or suspected disc-associated low-back pain is education and active nonoperative management; fusion, disc replacement, basivertebral ablation and intradiscal therapies apply only to selected phenotypes with very different evidence maturity (Qaseem 2017, PMID 28192789; Fischgrund 2018, PMID 29423885; Furunes 2018, PMID 29794581). Its deliberate sibling is spinal stenosis: degeneration can contribute to stenosis, but radiographic disc change, discogenic pain and neural compression are not interchangeable.
Start here: Overview · Research frontier: Open questions · Growth history: Curation log
Build at a glance¶
| Artifact | Completed scope |
|---|---|
| Canonical wiki pages | 18/18, all curated after independent citation audit |
| Unique live-verified PubMed papers cited | 348 |
| Live-verified ClinicalTrials.gov records tracked | 48 |
| Landmark evidence notes | 6 |
| Guideline/policy documents tracked | 17 |
| Quantitative statistics rows | 162 data rows |
| Patient-voice layer | 4 files; 12 verified organization/resource entries |
| Open questions | 32 (20 Tier 1; 12 Tier 2) |
| Unconnected-dot hypotheses | 20 |
Reading paths¶
| Need | Suggested path |
|---|---|
| Understand what DDD does—and does not—mean | Overview → Nomenclature and diagnostic validity → Imaging and grading |
| Understand biology and risk | Disc anatomy and biomechanics → Cellular and molecular degeneration → Genetics and environmental risk |
| Work through a clinical presentation | Discogenic pain and differential → Red flags and safety → Conservative treatment |
| Compare procedures and surgery | Injections and ablative procedures → Fusion and disc replacement → Outcomes and measurement |
| Assess emerging treatments | Regenerative and biologic therapy → Biomarkers → Clinical-trials landscape |
| See policy and lived-experience context | Guidelines → Patient experience and advocacy → Patient-voice themes |
Pages¶
| File | Scope | Status |
|---|---|---|
| overview.md | Nomenclature, imaging–pain gap, biology and treatment map | curated |
| nomenclature-and-diagnostic-validity.md | DDD label, discogenic pain, nonspecific back pain and coding | curated |
| epidemiology-and-natural-history.md | Age patterns, progression, symptoms and global low-back burden | curated |
| disc-anatomy-and-biomechanics.md | Nucleus, annulus, endplate, loading, nutrition and failure | curated |
| cellular-and-molecular-degeneration.md | Matrix loss, inflammation, senescence, oxidative stress and innervation | curated |
| genetics-and-environmental-risk.md | Twin evidence, variants, smoking, obesity, work and injury | curated |
| imaging-and-grading.md | MRI features, Pfirrmann, Modic change and asymptomatic findings | curated |
| discogenic-pain-and-differential.md | Phenotyping, referred/radicular pain, hip/SI and visceral mimics | curated |
| conservative-treatment.md | Education, exercise, rehabilitation, medicines and behavioral care | curated |
| injections-and-ablative-procedures.md | Intradiscal approaches, epidural use and basivertebral ablation | curated |
| fusion-and-disc-replacement.md | Indications, comparative trials, adjacent disease and reoperation | curated |
| regenerative-and-biologic-therapy.md | Cells, growth factors, hydrogels, gene therapy and trial quality | curated |
| outcomes-and-measurement.md | Pain, ODI, function, return to work and imaging endpoints | curated |
| guidelines.md | International recommendations, agreements and disagreements | curated |
| biomarkers.md | Inflammatory, imaging, biomechanical and molecular candidates | curated |
| clinical-trials-landscape.md | Rehabilitation, procedures, devices and regeneration trials | curated |
| patient-experience-and-advocacy.md | Diagnostic labeling, fear, work, access and patient priorities | curated |
| red-flags-and-safety-concerns.md | Cancer, infection, fracture, cauda equina, myelopathy and procedural risk | curated |
Literature layer¶
| Artifact | Contents |
|---|---|
| BIBLIOGRAPHY.md | Deduplicated bibliography of all 348 cited PMIDs, tagged and mapped to pages |
| Landmark notes | Structured notes on asymptomatic imaging, Pfirrmann grading, twin evidence, STarT Back, BVN ablation and disc progenitor cells |
| Guideline registry | Seventeen international guideline/policy documents, status, scope and disagreements |
| Statistics | Source-, year-, population- and method-qualified quantitative claims |
| Patient voice | Methods, themes, organizations, sources and geographic/selection limitations |
Curation state¶
This condition is audited as of 2026-08-30. All 18 canonical pages are curated: every PMID and NCT identifier resolved live, full-reference metadata matched, quantitative claims were checked against available abstracts or records, and dated absence claims were re-searched. Known evidence constraints—especially the absence of a gold standard for discogenic pain, inconsistent phenotype definitions and sparse patient-voice evidence outside high-income English-speaking settings—remain explicit evidence gaps rather than inferred conclusions.